This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giaccone, G. Articles by Capranico, G. Search for Related Content PubMed PubMed Citation Articles by Giaccone, G. Articles by Capranico, G.

Multidrug Sensitivity Phenotype of Human Lung Cancer Cells Associated with Topoisomerase II Expression

National Cancer Institute-Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Marylandt [G. G., A. F. G.], and Division of Experimental Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy [F. Z., G. C.]

Patterns of drug sensitivities in relation to topoisomerase II gene expression and activity were studied in eight human lung cancer cell lines not selected in vitro for drug resistance. The cytotoxicities of doxorubicin, etoposide, teniposide, cisplatin, camptothecin, and 5-fluorouracil were measured and, remarkably, these unselected cell lines were shown to have a common pattern of multidrug sensitivity, i.e., a multidrug sensitivity phenotype. In fact, drug sensitivities were significantly correlated with each other in the studied cell lines, the correlation being best for the topoisomerase II-targeted agents and cisplatin, less strong with camptothecin, and weak with 5-fluorouracil. Almost 1-log range difference of topoisomerase II gene expression was found in these cell lines, and this was not explained by the cell-doubling time or cell cycle distribution. The level of topoisomerase II gene expression was positively and highly correlated with the cell sensitivity to epipodophyllotoxins, doxorubicin, and cisplatin in seven cell lines. Although weaker, an association was also observed between topoisomerase II gene expression and camptothecin cytotoxicity, while no association was observed with 5-fluorouracil. However, a non-small cell lung cancer cell line with neuroendocrine properties had very low levels of expression of the topoisomerase II gene, despite being highly sensitive to all drugs tested. The levels of topoisomerase I gene expression were not found to be correlated with the cytotoxicity of any drug tested. A specific enzymatic activity assay and a teniposide-stimulated DNA cleavage assay showed that the extent of active topoisomerase II present in nuclear extracts paralleled the level of topoisomerase II gene expression. Furthermore, in addition to the normal transcript, an abnormally sized topoisomerase II message and a rearrangement of the topoisomerase II gene were detected in a poorly sensitive small cell lung cancer cell line. Therefore, low levels of topoisomerase II gene expression, and possibly mutations, may predict a reduced sensitivity of unselected human lung cancer cell lines to several drugs, including agents with a cellular target other than topoisomerase II. It is hypothesized that topoisomerase II might be involved in a common pathway of cell death induced by drugs in tumor cell lines which present a multidrug sensitivity phenotype.

¹ To whom requests for reprints should be addressed, at present address: Department of Oncology, Free University Hospital, 1117 De Boelelaan, HV 1081, Amsterdam, the Netherlands.

² Present address: University of Texas Southwestern Medical Center, Dallas, TX 75235.

³ Present address: Department of Pathology, University Hospital, Nijmegen, The Netherlands.

Received 6/26/91. Accepted 1/20/92.

This article has been cited by other articles:

				M. Provencio, C. Corbacho, C. Salas, I. Millan, P. Espana, F. Bonilla, and S. Ramon Cajal The Topoisomerase II{alpha} Expression Correlates with Survival in Patients with Advanced Hodgkin's Lymphoma Clin. Cancer Res., April 1, 2003; 9(4): 1406 - 1411. [Abstract] [Full Text] [PDF]

				D. W. Stacey, M. Hitomi, and G. Chen Influence of Cell Cycle and Oncogene Activity upon Topoisomerase IIalpha Expression and Drug Toxicity Mol. Cell. Biol., December 15, 2000; 20(24): 9127 - 9137. [Abstract] [Full Text]

				A.-M. C. Dingemans, M. A. Witlox, R. A. L. M. Stallaert, P. van der Valk, P. E. Postmus, and G. Giaccone Expression of DNA Topoisomerase II{{alpha}} and Topoisomerase II{beta} Genes Predicts Survival and Response to Chemotherapy in Patients with Small Cell Lung Cancer Clin. Cancer Res., August 1, 1999; 5(8): 2048 - 2058. [Abstract] [Full Text] [PDF]

				S.-W. Ng, J. P. Eder, L. E. Schnipper, and V. T. W. Chan Molecular Cloning and Characterization of the Promoter for the Chinese Hamster DNA Topoisomerase IIalpha Gene J. Biol. Chem., October 27, 1995; 270(43): 25850 - 25858. [Abstract] [Full Text] [PDF]

				P. C. Goswami, J. Sheren, L. D. Albee, A. Parsian, J. E. Sim, L. A. Ridnour, R. Higashikubo, D. Gius, C. R. Hunt, and D. R. Spitz Cell Cycle-coupled Variation in Topoisomerase IIalpha mRNA Is Regulated by the 3'-Untranslated Region. POSSIBLE ROLE OF REDOX-SENSITIVE PROTEIN BINDING IN mRNA ACCUMULATION J. Biol. Chem., December 1, 2000; 275(49): 38384 - 38392. [Abstract] [Full Text] [PDF]